Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEV-TASIRI in Metastatic Colorectal Cancer
NCT06242067Phase 2Recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Apr 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of trifluridine + tipiracil, irinotecan, bevacizumab in metastatic colorectal cancer (mCRC), sponsored by Qilu Hospital of Shandong University. Started Apr 2023; status: recruiting.
02
Drugs
trifluridine + tipiracilirinotecanbevacizumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT06242067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06242067.